- Home
- / Monte Rosa Therapeutics
Monte Rosa Therapeutics
Stock Price
$9.4
2024-10-29
Market Capitalization
$575.1 M
2024-10-29
Revenue
$123.7 M
FY, 2025
Monte Rosa Therapeutics Summary
Company Summary
- Overview
- Monte Rosa Therapeutics is a biopharmaceutical company that develops cancer therapeutics intended to modulate protein degradation pathways. Its technology treats cancer cells through small-molecule drugs that reprogram ubiquitin ligases to eliminate disease drivers.
- Type
- Public
- Status
- Active
- Founded
- 2018
- HQ
- Boston, MA, US | view all locations
- Website
- https://www.monterosatx.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Ajim Tamboli, Chief Financial Officer
Sharon Townson, Chief Technology Officer
Owen Wallace, Chief Scientific Officer
LocationsView all
6 locations detected
Boston, MA HQ
United States
645 Summer St
Boston, MA
United States
40 Guest St
Cambridge, MA
United States
One Broadway, 1 Broadway 14th floor
Basel, BS
Switzerland
Aeschenvorstadt 36
Basel, BS
Switzerland
Hochbergerstrasse 60C
Basel, BS
Switzerland
Klybeckstrasse 191/136
Monte Rosa Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $4.2M
- Net income (Q1, 2026)
- ($44.5M)
- Cash (Q1, 2026)
- $159.9M
- EBIT (Q1, 2026)
- ($50.0M)
- Enterprise value
- $454.3M